JYP0322 tablets

DRUG2 trials

Sponsors

Guangzhou JOYO Pharma Co., Ltd

Conditions

NSCLC (Advanced Non-small Cell Lung Cancer)Non Small Cell Lung Cancer

Phase 3

JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs.

Not yet recruitingNCT07154368

Guangzhou JOYO Pharma Co., LtdNon Small Cell Lung Cancer

Start: 2025-09-23End: 2029-12-31Target: 207Updated: 2025-09-19

A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Not yet recruitingNCT07816380

Guangzhou JOYO Pharma Co., LtdNSCLC (Advanced Non-small Cell Lung Cancer)

Start: 2026-10-30End: 2029-12-30Target: 216Updated: 2026-09-15